Evoke Pharma, Inc.
Evoke Pharma, Inc. (EVOK) Stock Overview
Explore Evoke Pharma, Inc.’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
9.1M
P/E Ratio
-3.04
EPS (TTM)
$-1.23
ROE
-1.02%
EVOK Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Evoke Pharma, Inc. (EVOK) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
The current technical analysis reveals key indicators including an RSI of 88.61, suggesting the stock is in an overbought condition. Our forecasting models predict significant price movements, with a 12-month target of $2.29.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -3.04 and a market capitalization of 9.1M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.
Technical Indicators
Analyst Recommendations
Price Targets
Company Profile
Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It is developing Gimoti, a metoclopramide nasal spray that has completed Phase 3 clinical trials to treat symptoms associated with acute and recurrent diabetic gastroparesis in females. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.
Matthew J. D'Onofrio MBA
3
420 Stevens Avenue, Solana Beach, CA
2013